Results 71 to 80 of about 106,112 (301)

POS0646 NON-MEDICAL SWITCHING FROM TOCILIZUMAB TO SARILUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY [PDF]

, 2022
N. Den Broeder, Alfons A den Broeder, Lise M Verhoef, F. van den Hoogen, Aatke van der Maas, B. van den Bemt   +5 more
openalex   +1 more source

Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department [PDF]

, 2020
As of March 30th, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise.
Brown, Cortlyn, Coralic, Zlatan, Noble, Jeanne   +2 more
core  

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial

EBioMedicine, 2022
Summary: Background: We recently showed that interleukin (IL)-6 inhibition by tocilizumab improves myocardial salvage in ST-elevation myocardial infarction (STEMI). However, the mechanisms for this effect are not clear.
Camilla Huse, Anne Kristine Anstensrud, Annika E. Michelsen, Thor Ueland, Kaspar Broch, Sindre Woxholt, Kuan Yang, Kapil Sharma, Ingvild Maria Tøllefsen, Bjørn Bendz, Brage Høyem Amundsen, Jan Kristian Damås, Erlend Sturle Berg, Elisabeth Bjørkelund, Ana Quiles-Jiménez, Vigdis Bjerkeli, Christina Bendz, Ola Kleveland, Knut Haakon Stensaeth, Anders Opdahl, Nils-Einar Kløw, Geir Øystein Andersen, Rune Wiseth, Bente Halvorsen, Lars Gullestad, Ingebjørg Seljeflot, Pål Aukrust, Liv Osnes, Tuva B. Dahl   +28 more
doaj   +1 more source

POS0696 TREATMENT OF GIANT CELL ARTERITIS PATIENTS WITH ULTRA-SHORT GLUCOCORTICOIDS AND TOCILIZUMAB: ROLE OF IMAGING IN A PROSPECTIVE STUDY [PDF]

, 2023
Francesco Muratore, Giulia Cassone, Chiara Marvisi, Elena Galli, Luigi Boiardi, Giulia Besutti, Lorenzo Spaggiari, Massimiliano Casali, Pamela Mancuso, Annibale Versari, Paolo Giorgi Rossi, Carlo Salvarani   +11 more
openalex   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Review of tocilizumab in the treatment of rheumatoid arthritis

Biologics: Targets & Therapy, 2008
Yasuaki OkudaDepartment of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama-city, Ehime, JapanAbstract: Constitutively overproduced in proliferating synovial tissues, interleukin-6 (IL-6) is deeply involved in the pathology
Yasuaki Okuda
doaj  

Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study

Respiratory Research, 2021
Background Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched. Methods In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO2/FiO2 
Theodoros Karampitsakos, Elli Malakounidou, Ourania Papaioannou, Vasilina Dimakopoulou, Eirini Zarkadi, Matthaios Katsaras, Panagiota Tsiri, Georgios Tsirikos, Vasiliki Georgiopoulou, Ioanna Oikonomou, Christos Davoulos, Dimitrios Velissaris, Fotios Sampsonas, Markos Marangos, Karolina Akinosoglou, Argyris Tzouvelekis   +15 more
doaj   +1 more source

Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA)

EClinicalMedicine, 2022
Summary: Background: In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay.
Ivan O. Rosas, Norbert Bräu, Michael Waters, Ronaldo C. Go, Atul Malhotra, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Sinisa Savic, Ivor S. Douglas, Julia Garcia-Diaz, Mariam S. Aziz, Nichola Cooper, Taryn Youngstein, Lorenzo Del Sorbo, David J. De La Zerda, Andrew Ustianowski, Antonio Cubillo Gracian, Kevin G. Blyth, Jordi Carratalà, Bruno François, Thomas Benfield, Derrick Haslem, Paolo Bonfanti, Cor H. van der Leest, Nidhi Rohatgi, Lothar Wiese, Charles Edouard Luyt, Rebecca N. Bauer, Fang Cai, Ivan T. Lee, Balpreet Matharu, Louis Metcalf, Steffen Wildum, Emily Graham, Larry Tsai, Min Bao   +36 more
doaj   +1 more source

Castleman disease and lymphocytic interstitial pneumonia: a complex diagnostic and management challenge [PDF]

, 2016
No abstract ...
Bayes, Hannah K., Chalmers, George W., McInnes, Iain B.   +2 more
core   +1 more source